It’s the lucky biotech that has a short and sweet runway. Most companies bring a drug to market — and begin to bring in revenue — only after years or decades of work.

But a company backed by Atlas Venture that’s less than a year old is the first acquisition of 2019 for Novartis. The pharmaceutical giant is paying more than $300 million upfront for IFM Tre, a Boston-based startup, in a deal that could be worth more than $1.5 billion if the company’s drugs meet certain undisclosed milestones.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy